Analysis of information sources in references of the Wikipedia article "Olanzapină" in Romanian language version.
At week 12, the olanzapine-treated group had more weight gain, a higher increase in [ body mass index ], and a higher proportion of patients with a BMI increase of at least 1 unit compared with the quetiapine and risperidone groups (p<=0.01).Verificați datele pentru:
|archive-date=
(ajutor)|access-date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|access-date=
(ajutor)|access-date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|date=
(ajutor)|access-date=
(ajutor)|access-date=, |date=
(ajutor)|date=
(ajutor)Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. [...] ZYPREXA (olanzapine) is not approved for the treatment of elderly patients with dementia-related psychosis.
At week 12, the olanzapine-treated group had more weight gain, a higher increase in [ body mass index ], and a higher proportion of patients with a BMI increase of at least 1 unit compared with the quetiapine and risperidone groups (p<=0.01).Verificați datele pentru:
|archive-date=
(ajutor)Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. [...] ZYPREXA (olanzapine) is not approved for the treatment of elderly patients with dementia-related psychosis.